Logo image of NRX.CA

NUREXONE BIOLOGIC INC (NRX.CA) Stock Fundamental Analysis

TSX-V:NRX - TSX Venture Exchange - CA67059R1091 - Common Stock - Currency: CAD

0.55  -0.01 (-1.79%)

Fundamental Rating

1

Overall NRX gets a fundamental rating of 1 out of 10. We evaluated NRX against 0 industry peers in the Unkown industry. The financial health of NRX is average, but there are quite some concerns on its profitability. NRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRX has reported negative net income.
NRX had a negative operating cash flow in the past year.
NRX had negative earnings in each of the past 5 years.
In the past 5 years NRX always reported negative operating cash flow.
NRX.CA Yearly Net Income VS EBIT VS OCF VS FCFNRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

Industry RankSector Rank
ROA -117.16%
ROE -144.6%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRX.CA Yearly ROA, ROE, ROICNRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

NRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRX.CA Yearly Profit, Operating, Gross MarginsNRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

There is no outstanding debt for NRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRX.CA Yearly Shares OutstandingNRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
NRX.CA Yearly Total Debt VS Total AssetsNRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M

2.2 Solvency

NRX has an Altman-Z score of 16.08. This indicates that NRX is financially healthy and has little risk of bankruptcy at the moment.
NRX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 16.08
ROIC/WACCN/A
WACCN/A
NRX.CA Yearly LT Debt VS Equity VS FCFNRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1M -1M 2M -2M -3M

2.3 Liquidity

A Current Ratio of 6.49 indicates that NRX has no problem at all paying its short term obligations.
A Quick Ratio of 6.49 indicates that NRX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.49
Quick Ratio 6.49
NRX.CA Yearly Current Assets VS Current LiabilitesNRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.07% over the past year.
EPS 1Y (TTM)20.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -15.87% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.11%
EPS Next 2Y5.41%
EPS Next 3Y-15.87%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRX.CA Yearly Revenue VS EstimatesNRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
NRX.CA Yearly EPS VS EstimatesNRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRX.CA Price Earnings VS Forward Price EarningsNRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRX.CA Per share dataNRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1

4.3 Compensation for Growth

A cheap valuation may be justified as NRX's earnings are expected to decrease with -15.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.41%
EPS Next 3Y-15.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUREXONE BIOLOGIC INC

TSX-V:NRX (3/7/2025, 7:00:00 PM)

0.55

-0.01 (-1.79%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-27 2024-11-27/bmo
Earnings (Next)03-27 2025-03-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.26%
Ins Owner ChangeN/A
Market Cap40.78M
Analysts84.44
Price Target2.89 (425.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)33.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.71
P/tB 9.71
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.16%
ROE -144.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1367.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.49
Quick Ratio 6.49
Altman-Z 16.08
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
EPS Next Y11.11%
EPS Next 2Y5.41%
EPS Next 3Y-15.87%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.34%
OCF growth 3YN/A
OCF growth 5YN/A